Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

455results about How to "Improve efficiency and quality" patented technology

Controlled release oxycodone compositions

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Owner:PURDUE PHARMA LP +2

Controlled release oxycodone compositions

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Owner:PURDUE PHARMA LP +3

Controlled release oxycodone compositions

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng / ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng / ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Owner:OSHLACK BENJAMIN +3

Controlled release oxycodone compositions

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng / ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng / ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Owner:PURDUE PHARMA LP +1

Air sterilizing assembly

Air disinfection device comprises a body that houses the power supply and control unit comprising a storage capacitor, a high-voltage DC power supply, an ignition pulse generator, a ferrite-core pulse transformer and a program control unit, and an ultraviolet radiation source mounted on the body in the form of a pulse gas discharge lamp enclosed in a tubular cooled casing transparent to bactericidal radiation. The storage capacitor and the pulse gas discharge lamp form a discharge circuit connected to the ignition pulse generator through the ferrite-core pulse transformer. The pulse gas discharge lamp is installed in a casing transparent to bactericidal radiation with convection air cooling capabilities provided by natural draft produced inside the casing, wherein the casing has one or several upper-level orifices in its upper part and some lower-level orifices in its lower part, with the following ratio of parameters:
h·Supper2·Slower2Supper2+Slower2=1A·C2U04F2
where h is the distance between the orifices of the upper and lower levels, m; Supper—total surface area of the orifice in the upper level, m2; Slower—total surface area of the orifice in the lower level, m2; A=(2÷30)·1013J2/m5s2—power correlation coefficient; C—capacity of energy storage capacitor, F; U0—charge voltage of the energy storage capacitor, V; F—pulse repetition rate of the ignition pulse generator, Hz.
Owner:NAUCHNO PROIZVODSTVENNOE PREDPRIYATIE MELITTA LLC

Hoisting method for overhauling and dismantling vaporization flue fixed at first section of converter

The invention relates to a hoisting method for overhauling and dismantling a vaporization flue fixed at the first section of a converter, belonging to a hoisting device for equipment. The hoisting method comprises the following specific steps of: firstly, arranging a hoisting jig; secondly, arranging hoisting points and a hoisting steel wire rope; thirdly, dismantling a support seat; and fourthly, dismantling the vaporization flue fixed at the first section: (1) horizontal positioning: enabling the vaporization flue fixed at the first section to be horizontally placed on a body of the converter; (2) moving the vaporization flue fixed at the first section rightwards: enabling the vaporization flue fixed at the first section and the converter to commonly rotate and move rightwards to the inside of an adding bay of the converter; and (3) lifting the vaporization flue fixed at the first section: lifting a secondary lifting rope and a main lifting rope for an adding bay traveling crane, lifting the vaporization flue fixed at the first section and moving the adding bay traveling crane to hoist the vaporization flue fixed at the first section to the designated position to finish the dismantling and hoisting work. The efficiency and the quality for overhauling and dismantling the vaporization flue fixed at the first section of the converter are effectively improved, the construction cost is reduced and the overhaul time is shortened.
Owner:CHINA MCC17 GRP

Rapid configuration and test method for programmable logic device in system programming

The invention discloses a rapid configuration and test method for a programmable logic device in system programming. According to the method, ISP (in-system programmable) state machine configuration codes are acquired by one-time programming and four-time transcoding. The rapid configuration and test method includes the steps of conducting test configuration program development in a corresponding development environment of the programmable logic device to acquire original configuration codes; converting the original configuration codes into an SVF (serial vector format) file through a conversion tool; converting the SVF file into a PCF (portable compiled format) file; generating an ATP file by a C-language transcoding program; converting the ATP file into a Pattern file, and using an ATE (automatic test equipment) automatic test system for rapid configuration and test. The rapid configuration and test method for the programmable logic device in system programming has the advantages that the ISP state machine configuration codes can be generated automatically, and multi-time configuration and test operation can be conducted, so that test fault coverage rate is increased greatly, and the test problem of the programmable logic device is solved; the rapid configuration and test method is universal.
Owner:58TH RES INST OF CETC

Controlled release oxycodone compositions

A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng / ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng / ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng / ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed.
Owner:PURDUE PHARMA LP +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products